We are live on ! Find out more
VRAY

ViewRay, Inc.

Delisted

VRAY was delisted on the 25th of July, 2023.

145 hedge funds and large institutions have $288M invested in ViewRay, Inc. in 2019 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 55 increasing their positions, 42 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more call options, than puts

Call options by funds: $7.18M | Put options by funds: $3.99M

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

31% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 42

5% more funds holding

Funds holding: 138145 (+7)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

69% less capital invested

Capital invested by funds: $931M → $288M (-$644M)

Holders
145
Holders Change
+7
Holders Change %
+5.07%
% of All Funds
3.18%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
30
Increased
55
Reduced
42
Closed
22
Calls
$7.18M
Puts
$3.99M
Net Calls
+$3.19M
Net Calls Change
+$7.04M
Name Holding Trade Value Shares
Change
Change in
Stake
PVI
26
Pura Vida Investments
New York
$2.13M -$681K -115,006 -14%
RPAM
27
Rhenman & Partners Asset Management
Sweden
$1.84M -$169K -28,589 -4%
RA
28
Royce & Associates
New York
$1.8M +$729K +123,000 +25%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.66M +$1.4M +236,425 +70%
Goldman Sachs
30
Goldman Sachs
New York
$1.26M -$14.2M -2,394,140 -85%
GGHC
31
Gilder Gagnon Howe & Co
New York
$1.26M +$67.5K +11,388 +3%
PCM
32
Penn Capital Management
Pennsylvania
$1.23M -$764K -128,907 -23%
DM
33
Deerfield Management
New York
$1.1M +$2.24M +378,623 New
SCM
34
Sterling Capital Management
North Carolina
$1.06M +$825K +139,323 +61%
Balyasny Asset Management
35
Balyasny Asset Management
Illinois
$1.03M +$2.11M +356,340 New
Charles Schwab
36
Charles Schwab
California
$1.03M -$42.3K -7,143 -2%
KBG
37
Kahn Brothers Group
New York
$985K +$1.35M +227,300 +202%
Wells Fargo
38
Wells Fargo
California
$970K +$408K +68,880 +26%
SSA
39
Schonfeld Strategic Advisors
New York
$958K -$511K -86,165 -21%
Prudential Financial
40
Prudential Financial
New Jersey
$948K -$78.4K -13,230 -4%
Morgan Stanley
41
Morgan Stanley
New York
$924K +$797K +134,490 +73%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$910K +$1.2M +202,562 +182%
SEI Investments
43
SEI Investments
Pennsylvania
$897K +$754K +127,199 +70%
N
44
Nuveen
North Carolina
$743K +$106K +17,857 +7%
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$739K -$2.72M -458,359 -64%
Two Sigma Investments
46
Two Sigma Investments
New York
$616K +$1.26M +212,322 New
MCM
47
Moore Capital Management
New York
$580K
CS
48
Candriam SCA
Luxembourg
$538K +$587K +99,000 +115%
Luther King Capital Management (LKCM)
49
Luther King Capital Management (LKCM)
Texas
$460K -$1.12M -189,415 -54%
TI
50
Telemetry Investments
New York
$440K +$439K +74,057 +96%

VRAY Hedge Fund Activity: Q3 2019 in Review

145 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ViewRay, Inc. (VRAY) for Q3 2019, worth a combined $288M — down 69% from $931M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new VRAY positions and 22 closed out — a net gain of 8 holders — while 55 added to existing stakes and 42 trimmed.

The largest buyer was Lansdowne Partners (UK), opening a new position worth an estimated $14.2M. The largest seller was OrbiMed, exiting entirely with an estimated $45.4M sold.

  • 145 institutional investors held ViewRay, Inc. (VRAY) as of Q3 2019, up from 138 in Q2 2019.
  • Funds reported $288M of ViewRay, Inc. stock for Q3 2019, down 69% quarter-over-quarter.
  • 30 funds opened new ViewRay, Inc. positions in Q3 2019 and 22 closed out, a net change of +8 holders.
  • The largest ViewRay, Inc. buyer in Q3 2019 was Lansdowne Partners (UK), an estimated $14.2M added.
  • The largest ViewRay, Inc. seller in Q3 2019 was OrbiMed, an estimated $45.4M sold.

Based on aggregated 13F filings for Q3 2019.